Evaluating Potential Endocrine Disrupting Effects of Chemicals in Humans: Challenges for Litigation
October 30, 2012
The concept of endocrine disruption has spawned controversial claims that low-level exposures to synthetic chemicals (such as PCBs, dioxins, and some pesticides, pharmaceuticals, and food additives), and certain naturally occurring substances in our environment may disrupt hormonal processes. Endocrine disruption has been alleged to result in such adverse human health effects as diabetes, thyroid disease, endometriosis, infertility, prostate cancer, and even obesity.
The potential for exposure to alleged “endocrine disrupting chemicals” (EDCs) has implicated materials in a variety of everyday items. Some groups say these claimed EDCs pose significant risks of substantial harm to children and adults, even at very low concentrations. Among the implicated items are toys, food, drinking water, consumer products, and cosmetics.
Over the past nine months, new regulatory screening regimes have been introduced by the U.S. EPA’s Endocrine Disruptor Screening Program (EDSP) and the European Union’s Directorate-General for the Environment. These regimes will assist the agencies in preparing a “priority list” of substances to be screened, collecting hazard information on individual chemicals, and developing scientific criteria for the identification of what will be regulated as “actual” endocrine disruptors.
Join Exponent and Crowell & Moring, LLP for a discussion of current controversies that surround the regulation, the risk assessment of potential EDCs, and the impending legal challenges facing product manufacturers and distributors.
Please click here to register.
This webinar is approved for 1.0 CLE credit by the State Bar of California. All attendees will receive a certificate of attendance to use for individual applications to other states.
James C. Lamb, IV, Ph.D., DABT, Fellow ATS
Principal Scientist, Exponent
Barbara H. Neal, DABT
Senior Managing Scientist, Exponent
Crowell & Moring Participant(s)